{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:23Z","timestamp":1790153303452,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ymgme.2012.04.027","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T09:40:38Z","timestamp":1336556438000},"page":"301-309","source":"Crossref","is-referenced-by-count":65,"title":["The impact of antibodies in late-onset Pompe disease: A case series and literature review"],"prefix":"10.1016","volume":"106","author":[{"given":"Trusha T.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhrad G.","family":"Banugaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Wenninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.04.027_bb0005","series-title":"Scriver's OMMBID \u2014 The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2009"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0010","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","article-title":"Progress in enzyme replacement therapy in glycogen storage disease type II","volume":"2","author":"Angelini","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0040","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ymgme.2007.04.018","article-title":"Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease","volume":"91","author":"Hawes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease in infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mus.21933","article-title":"Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid alpha-glucosidase activity","volume":"43","author":"Bali","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0075","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","author":"Regnery","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0085","first-page":"S184","article-title":"Use of the six\u2010minute walk test as an endpoint in late-onset Pompe disease","author":"Florence","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain\u2013Barre syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0095","unstructured":"M.K. J.E. Ware Jr, J. B. Bjorner, D.M. Turner-Bowker, B. Gandek, M.E Maruish., User's manual for the SF-36v2 health survey., in: Q. Incorporated. (Ed.), Lincoln, RI., 2007."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0100","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (\u221213T\u2013>G) mutation in a majority of patients and a novel IVS10 (+1GT\u2013>CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul. Disord.: NMD"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1098-1004(1997)10:2<128::AID-HUMU5>3.0.CO;2-G","article-title":"Glycogenosis type II: a juvenile-specific mutation with an unusual splicing pattern and a shared mutation in African Americans","volume":"10","author":"Adams","year":"1997","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V82.5.1402.1402","article-title":"Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase","volume":"82","author":"Richards","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pcl.2008.01.010","article-title":"Advances in hemophilia: experimental aspects and therapy","volume":"55","author":"Rodriguez","year":"2008","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0145","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0150","first-page":"169","article-title":"Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin","volume":"9","author":"Marshall","year":"1988","journal-title":"Diabetes Res"},{"issue":"Suppl. 5","key":"10.1016\/j.ymgme.2012.04.027_bb0155","first-page":"42","article-title":"Antibodies against rHuEPO: native and recombinant nephrology, dialysis, transplantation","volume":"17","author":"Casadevall","year":"2002","journal-title":"Off. Publ. Eur. Dial. Transplant Assoc. Eur. Renal Assoc."},{"issue":"3","key":"10.1016\/j.ymgme.2012.04.027_bb0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry","volume":"105","author":"Wilcox","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0170","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0175","unstructured":"Cerezyme, [Package Insert], Genzyme Corporation, Cambridge (MA), 1994."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0180","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0185","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years","author":"Angelini","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0190","unstructured":"Myozyme, [Package Insert], Genzyme Corporation, Cambridge (MA), 2006."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1529-1049(02)00049-1","article-title":"Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders","volume":"2","author":"Richards","year":"2002","journal-title":"Clin. Appl. Immunol. Rev."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/mgme.2000.2979","article-title":"Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats","volume":"69","author":"Turner","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2230.2001.00852.x","article-title":"Epitope spreading: protection from pathogens, but propagation of autoimmunity?","volume":"26","author":"Powell","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.22136","article-title":"Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease","volume":"44","author":"Banati","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2012.04.027_bb0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.04.027_bb0220","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212001709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212001709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T09:55:23Z","timestamp":1594115723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1096719212001709"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.04.027","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}